GLP-1 drugs linked to nutritional deficiencies in 16% of pediatric patients
Study reveals critical gaps in nutritional support for children on weight-loss medications
1Alarming deficiency rates
A study of 2,031 children aged 10-17 on GLP-1 medications found 16.8% developed nutritional deficiencies within one year of treatment. Vitamin D deficiency was most prevalent at 12.4%. These drugs, including liraglutide (78.6% of prescriptions), are increasingly used for weight management and diabetes in pediatric populations despite these emerging risks.
2Critical growth period risks
Adolescence requires substantial nutritional support for bone development and biological changes. GLP-1 medications' appetite suppression effects may interfere with this, potentially causing lasting skeletal and developmental impacts. Deficiencies in iron and calcium during this phase are particularly concerning for long-term health outcomes.
3Inadequate nutritional support
Only 5% of pediatric patients received nutritional counseling within 30 days of starting GLP-1 therapy, with less than 25% receiving it within six months. This gap occurs despite nutrients like vitamin D being crucial during puberty. The study suggests proactive nutritional management should accompany medication initiation.
4Prescription patterns revealed
Liraglutide (marketed as Victoza and Saxenda) dominated pediatric GLP-1 prescriptions at 78.6%. Dulaglutide (Trulicity) accounted for 10.4%, while semaglutide (Ozempic, Wegovy) represented 9.1%. The national claims data covered over 100 million patients, with 2,031 meeting study criteria for analysis.
5Study methodology insights
Researchers analyzed administrative claims data from 2017-2022, focusing on continuously enrolled patients without prior deficiency diagnoses. The study excluded children with pre-existing nutritional issues to isolate medication effects. This approach provided a clear view of treatment-emergent deficiencies.
6Clinical practice implications
Findings suggest nutritional monitoring should begin concurrently with GLP-1 prescriptions rather than waiting for deficiency detection. Current practices may leave growing children vulnerable during critical developmental windows when nutritional needs are highest.
7Researcher recommendations
Senior author Dr. Justin Ryder emphasizes proactive nutritional management for pediatric GLP-1 users. The study calls for integrating dietary counseling into treatment plans from initiation, particularly for adolescents undergoing rapid physical development and bone growth.
8Broader healthcare impact
As GLP-1 use expands in pediatric populations, these findings highlight systemic gaps in nutritional support protocols. The 16.8% deficiency rate underscores the need for updated clinical guidelines addressing medication-associated nutritional risks during childhood development.